Alfred Sandrock
Biogen Investigational Drug Shows Early Promise
Oct 11, 2016 at 02:55 pm by Staff
Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, publis.... Read More